CT
PTGX icon

Clearstead Trust’s Protagonist Therapeutics PTGX Stock Holding History

Clearstead Trust’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-21
Closed -$1.4K – 1412
2025
Q3 		$1.4K Hold
21
– – ﹤0.01% 1114
2025
Q2 		$1.16K Buy
+21
New +$1.01K ﹤0.01% 1108

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Clearstead Trust's PTGX Position: Q4 2025 in Review

Clearstead Trust sold out of Protagonist Therapeutics (PTGX) in Q4 2025, closing a stake of 21 shares — an estimated $1.4K sold.

Clearstead Trust first reported a position in PTGX in Q2 2025 and held it in 2 quarters. The position peaked at $1.4K in Q3 2025. 316 funds tracked by Wall St. Rank hold PTGX as of Q4 2025.

  • Clearstead Trust reported no remaining Protagonist Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Clearstead Trust sold 21 Protagonist Therapeutics shares in Q4 2025, an estimated $1.4K.
  • Clearstead Trust first reported a position in Protagonist Therapeutics in Q2 2025 and held it in 2 quarters.
  • Clearstead Trust's Protagonist Therapeutics position peaked at $1.4K in Q3 2025.
  • 316 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2025.

Based on Clearstead Trust's 13F filing for Q4 2025, filed 9 Feb 2026.